These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 20490325

  • 1. Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker.
    Liu JJ, Shen R, Chen L, Ye Y, He G, Hua K, Jarjoura D, Nakano T, Ramesh GK, Shapiro CL, Barsky SH, Gao JX.
    Int J Clin Exp Pathol; 2010 Mar 20; 3(4):328-37. PubMed ID: 20490325
    [Abstract] [Full Text] [Related]

  • 2. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.
    Khande TA, Joshi AR, Khandeparkar SGS, Kulkarni MM, Gogate BP, Kakade AR, Sahu PD, Khillare CD.
    Indian J Cancer; 2020 Mar 20; 57(2):190-197. PubMed ID: 32445323
    [Abstract] [Full Text] [Related]

  • 3. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Enomoto Y, Murase K, Imamura M, Takatsuka Y, Sakita I, Hatada T, Miyoshi Y.
    Clin Breast Cancer; 2015 Jun 20; 15(3):204-11. PubMed ID: 25600243
    [Abstract] [Full Text] [Related]

  • 4. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.
    Curtit E, Nerich V, Mansi L, Chaigneau L, Cals L, Villanueva C, Bazan F, Montcuquet P, Meneveau N, Perrin S, Algros MP, Pivot X.
    Oncologist; 2013 Jun 20; 18(6):667-74. PubMed ID: 23723333
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
    Allott EH, Geradts J, Sun X, Cohen SM, Zirpoli GR, Khoury T, Bshara W, Chen M, Sherman ME, Palmer JR, Ambrosone CB, Olshan AF, Troester MA.
    Breast Cancer Res; 2016 Jun 28; 18(1):68. PubMed ID: 27349894
    [Abstract] [Full Text] [Related]

  • 9. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
    Ning SF, Li JL, Luo CP, Wei CH, Lu YK, Liu HZ, Wei WE, Zhang LT.
    Int J Clin Exp Pathol; 2014 Jun 28; 7(12):8740-7. PubMed ID: 25674240
    [Abstract] [Full Text] [Related]

  • 10. Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer.
    Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, Fujiwara S, Fu P, Honda Y, Iyama K, Iwase H.
    Mod Pathol; 2013 Jan 28; 26(1):79-86. PubMed ID: 22918168
    [Abstract] [Full Text] [Related]

  • 11. Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer.
    Kim SK, Jung WH, Koo JS.
    Int J Clin Exp Pathol; 2014 Jan 28; 7(6):3224-34. PubMed ID: 25031743
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.
    Batistatou A, Televantou D, Bobos M, Eleftheraki AG, Kouvaras E, Chrisafi S, Koukoulis GK, Malamou-Mitsi V, Fountzilas G.
    Anticancer Res; 2013 May 28; 33(5):2139-45. PubMed ID: 23645767
    [Abstract] [Full Text] [Related]

  • 13. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
    Wu NC, Wong W, Ho KE, Chu VC, Rizo A, Davenport S, Kelly D, Makar R, Jassem J, Duchnowska R, Biernat W, Radecka B, Fujita T, Klein JL, Stonecypher M, Ohta S, Juhl H, Weidler JM, Bates M, Press MF.
    Breast Cancer Res Treat; 2018 Nov 28; 172(2):327-338. PubMed ID: 30120700
    [Abstract] [Full Text] [Related]

  • 14. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
    Marotti JD, Collins LC, Hu R, Tamimi RM.
    Mod Pathol; 2010 Feb 28; 23(2):197-204. PubMed ID: 19898422
    [Abstract] [Full Text] [Related]

  • 15. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
    Rydén L, Jirström K, Haglund M, Stål O, Fernö M.
    Breast Cancer Res Treat; 2010 Apr 28; 120(2):491-8. PubMed ID: 20135347
    [Abstract] [Full Text] [Related]

  • 16. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
    Neely C, You S, Mendoza PM, Aneja R, Sahin AA, Li X.
    Breast J; 2018 Nov 28; 24(6):889-893. PubMed ID: 30230095
    [Abstract] [Full Text] [Related]

  • 17. Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma.
    Bhargava R, Lal P, Chen B.
    Diagn Mol Pathol; 2004 Dec 28; 13(4):213-6. PubMed ID: 15538111
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Expression of Hypoxia-Inducible Factor 1α in Invasive Breast Cancer with Metastasis to Lymph Nodes: Correlation with Steroid Receptors, HER2 and EPO-R.
    Badowska-Kozakiewicz A, Sobol M, Patera J.
    Adv Clin Exp Med; 2016 Dec 28; 25(4):741-50. PubMed ID: 27629849
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.